EGFR is the most frequently amplified/mutated growth factor receptor in primary HNSCC (The Cancer Genome Atlas Network, 2015), whose biological role has represented the rationale for the design of targeted anti‐EGFR treatments in combination with RT (Santuray et al,2018). Here, EGFR is linked to head and neck squamous cell carcinoma.